The APAC Radiopharmaceuticals market was valued at USD 1.1 billion in 2015 and is expected to witness a CAGR of 10.9% over the forecast period. Radiopharmaceuticals are being extensively used for molecular imaging, which involves the use of these molecules as biomarkers for specific molecular processes that determine the onset and/or progress of a disease is fueling the growth.
The Asian radiopharmaceutical market is expected to witness the fastest growth globally owing to increasing awareness among individuals and rising diagnostic rates. This in turn will fuel the demand for SPECT and PET devices. Over the forecast period, another phenomenon anticipated to boost market expansion is the rise in the number of healthcare facilities and improvement in care provision. Most of the countries in this region are developing nations and working towards the establishment of a stable and efficient healthcare system. Thus, it presents an excellent opportunity for the sale of radiopharmaceutical products, which finds vast application across the length and breadth of the healthcare industry.
According to the data published in the JurnalSainsNuklear Malaysian 2016, Tc-99m is used in more than 80.0% of the medical facilities in Malaysia and efforts toward ramping up self-production of this radiopharmaceutical is a growing focus within the healthcare fraternity of the region.
Radioisotopes are widely used as a diagnostic tool in the field of oncology, neurology, and cardiovascular diseases. Advancements in scanning technology are increasing the efficiency of diagnosis using radioisotopes, and as a result, application areas of existing radioisotopes are swiftly increasing. Widening applications of the existing products coupled with the introduction of newer radioisotopes for the diagnosis of respiratory-, bones-, and thyroid-related diseases are spurring the growth of nuclear medicines in the diagnostics market.
High accuracy, ability to integrate with other diagnostic techniques such as x-ray and growing awareness of this technique in the developing market are the major factors expected to fuel the growth of the diagnostic radiopharmaceuticals during the forecast period.
Radiopharmaceutical diagnostic techniques provide a better insight into the disease than the traditionally used diagnostic devices, including x-ray, ultrasound, CT, and MRI. SPECT and PET are the two widely used radiopharmaceutical diagnostic techniques that use radiotracers to study the targeted organ and tissues. High image clarity enables physicians to accurately decide the course of treatments, minimizing complications in trial and error treatments. Since these diagnostic techniques are new to the developing countries, the scope for the growth is huge. Lowering prices of the scanning devices and government support for the inclusion of radiopharmaceuticals are the factors driving the growth. On the other hand, factors that are anticipated to impede the growth include strict regulation of the radioactive elements, complex manufacturing processes, and comparatively high prices of the devices.
The APAC radiopharmaceutical market is expected to witness the fastest growth globally owing to increasing awareness among individuals and rising diagnostic rates. This in turn will fuel the demand for SPECT and PET devices. Over the forecast period, another phenomenon anticipated to boost expansion is the rise in the number of healthcare facilities and improvement in care provision. Most of the countries of this region are developing nations, working toward the establishment of a stable and efficient healthcare system. Thus, it presents an excellent opportunity for the sale of radiopharmaceutical products, which finds vast application across the length and breadth of the healthcare industry.
Key players of this industry include Nordion, Inc., Bayer AG, Mallinckrodt Public Limited company, GE Healthcare, Bracco Imaging S.P.A and government initiatives such as the Institute of Radioisotopes and The Australian Nuclear Science and Technology Organization (ANSTO).
Aggressive marketing of new products and technological advancements of the existing ones are the initiatives occurring in this industry. For instance, in March 2012, Nordion Inc. launched a new custom dose for TheraSphere. In addition to standard dose vial configurations, Nordion offers an expanded range of TheraSphere treatment options with a wide variety of custom doses. The tailored doses are designed to provide greater treatment flexibility to physicians, save administration time, and reduce product waste while limiting unnecessary radiation exposure to patients and healthcare professionals.
In January 2023, Jubilant Radiopharma, a division of Jubilant Pharma Ltd. announced approval from the U.S. FDA for Company’s new drug application (NDA) Tc 99m. It is used in the diagnosis of urinary tract obstruction, calculi, and renal failure in adults and pediatric patients.
In February 2022, Applied Molecular Therapies (AMT) announced a TGA license upgrade for the GMP manufacture of prostate cancer therapy known as Lu(n.c.a.)-PSMA-Therapy.
In November 2021, The Australian Nuclear Science & Technology Organisation (ANSTO) announced a joint venture with Cyclotek to build the first GMP theranostic radiopharmaceuticals in Australia. The new venture aimed to manufacture and supply therapeutic radiopharmaceuticals.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.